Summary The expression of P-glycoprotein in primary and recurrent human breast cancer was investigated by means of immunohistochemistry, using a monoclonal antibody (C219) and the streptavidin-biotin-peroxidase method. Twelve patients received no chemotherapeutic treatment. The other II patients were treated with chemotherapy, and all developed clinical resistance to it. No or only minimal reactivity was found in specimens coming from the untreated patients (12 cases) or from patients treated with substances not involved in the multidrug resistance phenomenon (four cases). In contrast, three out of seven tumours from patients treated with multidrug resistance related substances showed clear reactivity (positive staining in more than 20% of the tumour cells). In one of these cases, where specimens of the tumour could be studied before and after treatment, an association between the latter and expression of P-glycoprotein was suggested. Finally, this marked expression of P-glycoprotein only took place in tumours treated over a longer space of time (five courses or more of multidrug resistance related chemotherapy).
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During the past few years, we have begun to gain insight into the mechanisms by which tumour cells become resistant to a certain kind of chemotherapy (Moscow & Cowan, 1988; Tsuruo, 1988) . In this context, the connection between the so-called 'multidrug resistance phenotype' (MDR) and the expression of a 170 kDa membrane glycoprotein (usually referred to as P-170 or P-glycoprotein) has been clearly established in model tumours (Juliano & Ling, 1976; Kartner et al., 1983; Volm et al., 1987 
Materials and methods

Tumours
The tumour specimens were obtained from patients operated at the Department of Obstetrics and Gynaecology of the Heidelberg University Clinic. They were immediately frozen in liquid nitrogen at the time of operation and were kept at -70°C until they were used for the present investigation. Twelve tumours were from untreated patients (five primary tumours and seven local recurrences in patients under observation with no additional treatment after radical mastectomy) ( Table I ). The other 11 tumours were from patients clinically resistant to chemotherapy, i.e. with tumour progression or recurrence despite treatment.
Four of the patients were under treatment with substances not related with multidrug resistance (which will be referred to as non-MDR substances) at the time of operation. Two of them were receiving tamoxifen alone, one a combination of mitoxanthrone and prednisone (six courses) and one that Seven patients were under treatment with substances involved in multidrug resistance (MDR substances) . Two had received epirubicin, in combination with cyclophosphamide and 5-fluorouracil (FEC) (two and eight courses respectively); two had been treated with epirubicin plus vicrinstine, in combination with cyclophosphamide (VEC) (two and five courses, respectively); one had received 12 courses of epirubicin, in combination with tamoxifen; one had received two courses of vindesine and mitomicin C, followed by another two of VEC; and one had been treated with epirubicin, in combination with ifosfamide (two courses), followed by vindesine plus cisplatin (three courses).
Cryostat sections of the tumour samples, 6 .tm thin, were made. They were allowed to dry overnight, then fixed in cold acetone (-20°C ) and stored at -20°C until they were examined.
Immunohistochemistry
The monoclonal antibody used for P-glycoprotein detection was the C219 antibody originally developed by Kartner and Ling. It recognises an epitope lying in a cytoplasmic domain, 200 amino acids long, of the C-terminal region of the Pglycoprotein polypeptide .
The sections were rehydrated in PBS and afterwards quenched for the blocking of endogenous peroxidase activity in 0.3% H202/methanol. The monoclonal first antibody (C219; Centocor, Malvern, PA, USA) was then applied at a concentration varying between 2.5 and 10 lg ml', and incubated overnight at 4°C. Afterwards, the second biotinylated antimouse antibody (Amersham) and the streptavidin-biotinylated-peroxidase complex (Amersham) were applied in successive steps. Staining was performed by means of 3-amino-9-ethylcarbazole, giving a red-brown reaction product. The preparations were finally counterstained with Mayer's haematoxylin and mounted with glycerol gelatin. Negative controls for each sample were performed by incubation with normal mouse serum in substitution for the first antibody, at the same concentration, the rest of the procedure being carried out as described (Volm et al., 1988a) .
As positive controls we used colchicine-resistant CHO cell smears and preparations from a solid sarcoma-180 nude rat xenograft resistant to daunorubicin, expressing high levels of P-glycoprotein (Volm et al., 1988b (Volm et al., , 1989b Figure   1 al, a2, bl, b2). The intensity of the reaction was rather uniform, and never as high as that found in the experimental models used as positive controls (Figure 1, cl) but was nevertheless quite distinct. These three patients had received five, eight and 12 courses of MDR therapy, respectively, at the time of operation. One of these recurrent tumours was from a patient whose primary, untreated tumour could also be analysed in this study, and was negative (Figure 1 b3) . A relationship between MDR treatment, resistance and P-glycoprotein expression seems thus to exist in this case. Of the remaining four patients of this group, two had received only two courses of treatment, and the other two had received four and five courses, respectively. The tumours from these patients contained only single, isolated positively staining cells in two cases, and showed no reactivity at all in the other two. Although the patient number is low, these results seem to indicate that P-glycoprotein is expressed in this kind of tumours at significant levels only after a certain amount of MDR therapy has been delivered to them.
Discussion
Tumours arising in organs that normally express high levels of P-glycoprotein, such as the kidney, the adrenal or the colon (Thiebaut et al., 1987) are known to be intrinsically resistant to chemotherapy. This indirectly supports the view that P-glycoprotein may indeed play a role in the development of resistance. As for tumours originating in other tissues, with no original P-glycoprotein expression, there have already been reports of isolated cases, suggested a relationship between increasing levels of P-glycoprotein during treatment, and the appearance of clinical resistance, e.g. in ovarian carcinoma (Bell et al., 1985) and in leukaemia (Ma et al., 1987) .
The first case of detection of P-glycoprotein by means of immunocytochemistry in a human breast tumour has been reported by Sugawara et al. (1988) , who studied the distribution of P-170 in different normal human tissues and tumours with the help of the monoclonal antibody MRK 16. The first large study on human breast cancer and P-glycoprotein expression has recently been published by Merkel et al. (1988) who, using mRNA and DNA analysis, did not find a single case of MDR gene amplification among 248 mammary carcinomas, of which 22 were studied after induction (non-MDR) chemotherapy and seven after adriamycin therapy. RNA-analysis of 95 tumours from that same series was also negative, although 13 patients had been treated with regimens containing adriamycin. These results are in agreement with our own experience using the 265/F4 monoclonal antibody the authors used for selecting their cDNA clone. We also found no positive reaction for P-glycoprotein when using this monoclonal antibody on our mammary tumour material, whereas it yielded the expected results with renal tumours, normal kidney expressing high P-glycoprotein levels (the positive control used by Merkel et al., 1988) , normal liver and human leukaemias (Volm et al., 1989b) . Goldstein et al. (1989) found nine positive cases, of which two had been treated (kind of treatment not stated), among 57 breast cancers. They used the same methodology of mRNA measurements as Merkel et al. (1988) , who in their paper make the comment that their approach cannot exclude the existence of small tumour subpopulations expressing Pglycoprotein and that, alternatively, monoclonal antibodies directed against it could be used to detect P-glycoprotein by immunohistochemistry. This is the approach we have chosen.
Our results demonstrate that immunocytochemistry may be a useful method for the detection of P-glycoprotein in clinical material. Determination of m-RNA contents (Merkel et al., 1988; Goldstein et al., 1989) may be impractical in the clinical setting for several reasons: it is technically more cumbersome, implies the use of sophisticated laboratory material not present in every hospital and is more timeconsuming. Finally, at the present moment, it is still unclear whether only tumour cells express P-glycoprotein under treatment, or if the tumour cells expressing it are the most representative ones for the development of resistance to chemotherapy (Chan et al., 1988 be found only in the patient group having received MDR therapy in high doses, favour such a hypothesis. The presence of two control groups, one without any treatment and one with non-MDR treatment, where P-glycoprotein was not detected at any significant levels, validates this result. Its confirmation in larger series and for other tumours would open the possibility for including P-glycoprotein determinations into the planning scheme of tumour therapy. By detecting those tumours which express P-glycoprotein primarily, useless treatment with MDR chemotherapy could be avoided. There is also evidence that the functioning of P-glycoprotein can be effectively modulated by means of certain substances, notably verapamil, trifluoperazine and other membrane-active compounds, although the high doses necessary for obtaining this effect experimentally still preclude their use in patients .
In conclusion, P-glycoprotein is demonstrable in human mammary carcinomas by means of immunohistochemistry; it was present at clearly detectable levels only after treatment with chemotherapeutic substances related to the multidrug resistance phenomen; finally, its appearance may be related with the development of tumour resistance to MDR therapy. This method may prove to be of use in the future for clinical practice.
